| Literature DB >> 35813740 |
Takashi Sakai1, Atsushi Sano1, Hiroshige Shimizu2, Yoko Azuma1, Naohisa Urabe2, Kazutoshi Isobe2, Susumu Sakamoto2, Yujiro Takai2, Yoshitaka Murakami3, Kazuma Kishi2, Akira Iyoda1.
Abstract
Background: The indication for and the timing of surgery in patients with pleural infection remains unclear. Determining the need for surgery in patients with pleural infection may help in the early consultation of surgeons.Entities:
Keywords: Pleural infection; empyema; locule on anterior mediastinum side; multifocal locules; surgical indicator
Year: 2022 PMID: 35813740 PMCID: PMC9264076 DOI: 10.21037/jtd-21-1812
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 3.005
Figure 1Image findings of (A) multifocal locules (arrows) and (B) LAMS (circle) in a patient with pleural infection. LAMS, locule on the anterior mediastinum side.
Figure 2Treatment strategy for pleural infections at our institution. Non-surgical treatments are initially selected based on Light’s classification. ○: performed; △: performed with the following exceptions: only thoracentesis is performed for patients with type 1; a tube thoracotomy is performed for patients with type 3 and above (and objectively selected for patients with type 2). If a tube thoracostomy is not possible due to a lack of space or adhesion of the lungs, only thoracentesis and administration of antibiotics are performed initially (*). Irrigation and thrombolytics are used for patients with type 5 and above (and objectively selected for patients with type 3 and 4), except for the patients who are diagnosed with or suspected to have a fistula (**). If the patient improves after the initial treatment, patients are discharged with oral antibiotics and outpatient follow-up. Surgery is performed if the locule(s) remain and are not improved after the initial treatment, or if the symptoms, condition, or inflammation worsen. If the respiratory or general condition worsens rapidly or leads to sepsis, early surgery is performed to control the infection (***).
Figure 3Flowchart for patient selection. Patients were excluded if they were diagnosed with chronic empyema, postoperative empyema, retrograde infection, pleural infection with Aspergillus or tuberculosis, or empyema after bronchoscopy. The remaining 167 patients were included in the analyses. To identify the indicators for resistance to non-surgical therapy, patients were divided into two groups; patients cured by non-surgical therapy (n=94) and patients who were resistant to the initial non-surgical treatment (n=73); the latter included patients who underwent surgical intervention after the initial therapy (n=62) and those who showed recurrence or disease-related death after non-surgical therapy (n=11).
Patient characteristics
| Variables (n=167) | N (%) or median (range) |
|---|---|
| Age, years | 66 [26–89] |
| Male | 139 (83.2) |
| Body mass index, kg/m2 | 22.6 (12.2–38.4) |
| ECOG-PS 3–4 | 19 (11.3) |
| Smoker | 117 (70.1) |
| Pack-year smoking | 17 [0–145] |
| Heavy drinker | 40 (24.0) |
| From appearance of symptoms to hospitalization (days) | 7 [0–74] |
| PaO2/FiO2 | 341 [63–592] |
| Comorbidity/anamnesis | |
| Diabetes mellitus | 49 (29.3) |
| History of malignancy | 22 (13.2) |
| Stroke | 17 (10.2) |
| Chronic kidney disease (creatinine >1.5 mg/dL) | 15 (9.0) |
| Blood test | |
| C-reactive protein (mg/L) | 199 [10–401] |
| White blood cell (/µL) | 14,400 (1,100–75,300) |
| Albumin (g/dL) | 2.5 (1.6–3.9) |
| Side | |
| Right | 84 (50.3) |
| Left | 83 (49.7) |
| Detection of causative bacteria in pleural effusion | 99 (59.3) |
| Streptococcus anginous group | 43 (25.7) |
| Anaerobic bacteria | 38 (22.8) |
| Staphylococcus aureus | 10 (6.0) |
| Mixed aerobic and anaerobic bacteria | 12 (7.2) |
| First dose antibiotics | |
| β-lactamase | 80 (47.9) |
| Carbapenem | 58 (34.7) |
| Piperacillin/Tazobactum | 21 (12.6) |
| Others | 8 (4.8) |
| Procedure | |
| Tube thoracostomy | 157 (94.0) |
| Irrigation | 119 (71.3) |
| Thrombolytics | 100 (59.9) |
| Surgery | 62 (37.1) |
ECOG-PS, Eastern Cooperative Oncology Group-performance status.
The clinical and image findings of logistic analyses to identify the indicators for resistance to non-surgical therapy in patients with pleural infection (n=167)
| Variables | Reference | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | P | OR | 95% CI | P | |||
| Age >70 years | ≤70 years | 0.71 | 0.48–1.32 | 0.275 | ||||
| Sex: male | Female | 1.24 | 0.54–2.85 | 0.605 | ||||
| Body mass index >25 kg/m2 | ≤25 | 1.77 | 0.77–4.05 | 0.179 | ||||
| ECOG-PS 3–4 | 0–2 | 1.48 | 0.57–3.86 | 0.421 | ||||
| PaO2/FiO2 <300 | ≥300 | 0.85 | 0.45–1.60 | 0.621 | ||||
| Pack-year smoking>60 | ≤60 | 0.56 | 0.21–1.45 | 0.232 | ||||
| Comorbidity/anamnesis | ||||||||
| Diabetes mellitus | No | 1.71 | 0.87–3.34 | 0.118 | ||||
| Chronic kidney disease | No | 1.53 | 0.53–4.43 | 0.434 | ||||
| From appearance of symptoms to hospitalization >7 days | ≤7 days | 1.64 | 0.88–3.03 | 0.117 | 1.71 | 0.84–3.51 | 0.140 | |
| Fistula | No | 1.31 | 0.41–4.25 | 0.649 | ||||
| Septic shock at the hospitalization | No | 1.31 | 0.36–4.70 | 0.680 | ||||
| Serum albumin level <2.5 g/dL | ≥2.5 g/dL | 1.02 | 0.55–1.89 | 0.946 | ||||
| White blood cell >15,000/µL | ≤15,000/µL | 0.79 | 0.42–1.47 | 0.461 | ||||
| CRP >200 mg/L | ≤200 mg/L | 1.42 | 0.77–2.62 | 0.263 | ||||
| Pus | No | 1.11 | 0.56–2.21 | 0.755 | 1.08 | 0.43–2.70 | 0.873 | |
| Glucose <40 mg/dL (pleural effusion) | ≥40 mg/dL | 1.11 | 0.59–2.08 | 0.743 | 1.01 | 0.51–2.37 | 0.800 | |
| pH <7.2 (pleural effusion) | ≥7.2 | 1.53 | 0.79–2.96 | 0.211 | 1.49 | 0.63–3.50 | 0.356 | |
| Bacteria positive (pleural effusion) | Negative | 0.80 | 0.43–1.48 | 0.470 | 0.63 | 0.29–1.40 | 0.259 | |
| Image findings | ||||||||
| Pleural space anatomy >1/2 hemithorax | ≤1/2 hemithorax | 1.34 | 0.71–2.53 | 0.368 | 0.81 | 0.38–1.77 | 0.608 | |
| Locules | ||||||||
| Single locule | Not loculated | 0.52 | 0.44–5.04 | 0.522 | 1.73 | 0.49–6.17 | 0.397 | |
| Multiple locules without LAMS | Not loculated | 3.34 | 1.05–10.60 | 0.041* | 3.67 | 1.11–12.14 | 0.033* | |
| Single locule | 2.24 | 0.84–5.99 | 0.108 | 2.12 | 0.72–6.21 | 0.171 | ||
| Multiple locules + LAMS | Not loculated | 11.47 | 3.78–34.78 | <0.001* | 14.15 | 4.30–46.56 | <0.001* | |
| Single locule | 7.70 | 3.04–19.48 | <0.001* | 8.17 | 3.06–21.82 | <0.001* | ||
| Multiple locules without LAMS | 3.43 | 1.58–7.97 | 0.0041* | 3.86 | 1.52–9.77 | 0.0044* | ||
| Microbubbles | No | 1.06 | 0.51–2.19 | 0.885 | ||||
| Split Pleural Sign | No | 1.57 | 0.82–3.01 | 0.171 | ||||
*, significant difference (P<0.05). OR, odds ratios; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group-performance status; LAMS, locule on the anterior mediastinum side; CRP, C-reactive protein.
Comparison of the treatment and prognosis between the patients who treated underwent surgery within 7 days and over 7days of admission
| Outcome | Surgery ≤7 days (n=33) | Surgery >7 days (n=29) | P value |
|---|---|---|---|
| Duration between admission and surgery (average, days) | 2.9 | 18.6 | |
| Hospitalization (average, days) | 26.9 | 42.0 | 0.0071* |
| Using antibiotics (average, days) | 31.0 | 38.5 | 0.0619 |
| Duration of CRP improvement <30 days, n (%) | 23 (69.7) | 6 (20.7) | <0.0001* |
| Recurrence of empyema, n (%) | 0 (0.0) | 0 (0.0) | 0.2480 |
Surgery ≤7 days: patients underwent surgery within 7 days of admission; surgery >7 days: patients underwent surgery over 7 days of admission; duration of CRP improvement: CRP level improved within 10 mg/L during the observation period. *, significant difference (P<0.05). CRP, C-reactive protein.